GLP-1 receptor agonist: difference between revisions
Diff·revision 13 → 14·17:03, 6 Nov 2024
Difference between revision 13 and revision 14 of GLP-1 receptor agonist. 4 lines changed; the page grew by 232 bytes.
| Revision 13 — 00:26, 21 Oct 2024 LOD_Lorcan (talk) expand §Molecular strategies for half-life extension 6,307 bytes +187 | Revision 14 — 17:03, 6 Nov 2024 TriumphThad (talk) rm the comparison to a compound with no published head-to-head data 6,539 bytes +232 | ||
|---|---|---|---|
| 12 | | Oral peptide = [[Oral semaglutide]] | 12 | | Oral peptide = [[Oral semaglutide]] |
| 13 | | Small molecule = [[Orforglipron]] (investigational) | 13 | | Small molecule = [[Orforglipron]] (investigational) |
| + | 14 | <!-- Principal effects --> | |
| + | 15 | | Glycaemic = Glucose-dependent insulin release, glucagon suppression | |
| + | 16 | | Gastric = Delayed [[Gastric emptying|emptying]] | |
| + | 17 | | Central = Reduced appetite via [[Arcuate nucleus|hypothalamic]] circuits | |
| 14 | }} | 18 | }} |
| 15 | {{hatnote|For the endogenous hormone, see [[Glucagon-like peptide-1]]. For agonists acting at more than one incretin receptor, see [[Dual incretin agonist]].}} | 19 | {{hatnote|For the endogenous hormone, see [[Glucagon-like peptide-1]]. For agonists acting at more than one incretin receptor, see [[Dual incretin agonist]].}} |